Why???

Quote

Anonymous

Guest
Why are some of you so concerned about LC's talk? I did not hear anything that concerned me. I did hear that his expectation is for us to move business, but that is his job and ours as well. If we don't do that why would they need us? Please tell me specifically what he said that freaked so many people out? I guess I missed it.
 



Simple business in that a company needs to be generating sufficient revenue from product sales in order to be able to afford a sales force. Does the combination of company income from current product sales and product pipeline potential warrant a sales force of this particular size? You be the judge.
 



My personal opinion is that there were several undertones while he discussed the future of eritoran. I honestly think they know more than they are letting on and I don't think the picture is pretty for the hospital team.
 






Maybe primary care/specialty too! But since I am on the oncology side of things- his message hit me harder! Without eritoran and the loss of Fragmin- hospital will have nothing in the bag appropriate for hospitals. They surely don't need the hundred plus reps selling the oncology drugs.
 



Anonymous said:
Maybe primary care/specialty too! But since I am on the oncology side of things- his message hit me harder! Without eritoran and the loss of Fragmin- hospital will have nothing in the bag appropriate for hospitals. They surely don't need the hundred plus reps selling the oncology drugs.
Click to expand...

Yup, the hospital team is history. But most of you are not wanted by any other company. You apply to several positions and never get called. So your only option is to vent on cafe pharma about OB, about your DM, about LC, blah blah blah. It's always someone else that just doesn't see how skilled or important you are. The truth is you're not important. You could be replaced in 2 seconds.
 






Any time you hear language as serious as LC's coming from your CEO at a national meeting, you better be worried. Generally the situation is far worse than they let on. I would read between the lines on his speech (and every other executive address). Unless everything goes Eisai's way in the coming months approval-wise and A23 really picks up, expect some big changes.
 



Anonymous said:
Why are some of you so concerned about LC's talk? I did not hear anything that concerned me. I did hear that his expectation is for us to move business, but that is his job and ours as well. If we don't do that why would they need us? Please tell me specifically what he said that freaked so many people out? I guess I missed it.
Click to expand...

Out job is not about sales it is about HHC. Sales will come if we have a product that brings value after we think about the customer first.
 



Anonymous said:
Any time you hear language as serious as LC's coming from your CEO at a national meeting, you better be worried. Generally the situation is far worse than they let on. I would read between the lines on his speech (and every other executive address). Unless everything goes Eisai's way in the coming months approval-wise and A23 really picks up, expect some big changes.
Click to expand...

We have another winner. The only way to learn something at these meetings is to know that it's what they're not saying that is the real message. It must already be known that the data on Eritoran is a bust. Get ready.
 



Anonymous said:
Maybe primary care/specialty too! But since I am on the oncology side of things- his message hit me harder! Without eritoran and the loss of Fragmin- hospital will have nothing in the bag appropriate for hospitals. They surely don't need the hundred plus reps selling the oncology drugs.
Click to expand...

I have very very good information coming from home office. It does not matter if you are oncology or hospital. If ther eritorin data comes back bad, they ARE making cuts to the sales force. Eisai does not see oncology and or hospital as two seperate units. They are one unit. Just as many oncology reps will be let go as hospital reps. Get your metrics in order and your sales better be good. If you are an old oncology rep, but your old hospital rep has better #'s than you and meets their metrics, guess what, you are toast not them. There is no safe position if you are on the cco side of the business. And fyi...You better believe salary will play a BIG role is the downsizing.
 



Anonymous said:
I have very very good information coming from home office. It does not matter if you are oncology or hospital. If ther eritorin data comes back bad, they ARE making cuts to the sales force. Eisai does not see oncology and or hospital as two seperate units. They are one unit. Just as many oncology reps will be let go as hospital reps. Get your metrics in order and your sales better be good. If you are an old oncology rep, but your old hospital rep has better #'s than you and meets their metrics, guess what, you are toast not them. There is no safe position if you are on the cco side of the business. And fyi...You better believe salary will play a BIG role is the downsizing.
Click to expand...

Boy are you smart. I'm sure glad you have your home office source for such obvious information. If eritorin fails, do you think we'll all start selling lusedra?
 



Anonymous said:
Any time you hear language as serious as LC's coming from your CEO at a national meeting, you better be worried. Generally the situation is far worse than they let on. I would read between the lines on his speech (and every other executive address). Unless everything goes Eisai's way in the coming months approval-wise and A23 really picks up, expect some big changes.
Click to expand...

Tell me one thing that Eisai has done that worked out the way we hoped. Any guesses?

Nothing! No product launch, no acquisition, no expansion, has ever gone as planned. Companies do not suddenly figure it out, and then do well. If not for J&J and Pfizer, Eisai would be just another of those no-name companies out there. Sorry Kool Aid drinkers, but Eisai is only a place to get a paycheck till you are no longer needed. And that time is rapidly approaching.
 



Anonymous said:
Tell me one thing that Eisai has done that worked out the way we hoped. Any guesses?

Nothing! No product launch, no acquisition, no expansion, has ever gone as planned. Companies do not suddenly figure it out, and then do well. If not for J&J and Pfizer, Eisai would be just another of those no-name companies out there. Sorry Kool Aid drinkers, but Eisai is only a place to get a paycheck till you are no longer needed. And that time is rapidly approaching.
Click to expand...

halaven
 



Anonymous said:
I have very very good information coming from home office. It does not matter if you are oncology or hospital. If ther eritorin data comes back bad, they ARE making cuts to the sales force. Eisai does not see oncology and or hospital as two seperate units. They are one unit. Just as many oncology reps will be let go as hospital reps. Get your metrics in order and your sales better be good. If you are an old oncology rep, but your old hospital rep has better #'s than you and meets their metrics, guess what, you are toast not them. There is no safe position if you are on the cco side of the business. And fyi...You better believe salary will play a BIG role is the downsizing.
Click to expand...

Define "bad"...
 






Anonymous said:
You are wrong. Halaven was supposed to be a much bigger hit than this weak 3rd line+ drug and it was supposed to get to the market at least two years earlier.

Two years earlier of $500 million sales vs. now $50 million sales. Get around your head, seriously.
Click to expand...

True. Ixabepilone I believe beat Azi to the market.
 






Top Bottom
Back
Quote